Rationale: Conversion from a negative to positive QuantiFERON-TB test is indicative of Mycobacterium tuberculosis (Mtb) infection, which predisposes individuals to tuberculosis disease. Interpretation of serial tests is confounded by immunological and technical variability.
QuantiFERON-TB Gold In-Tube (QFT) (Qiagen, Hilden, Germany) measures immunological sensitization to Mycobacterium tuberculosis (Mtb) as a biomarker for Mtb infection. Compared with persistent QFT negativity, recent conversion from a negative to positive QFT test is associated with higher tuberculosis (TB) disease incidence (1, 2) .
In settings with a low incidence of TB disease, individuals with recent infection, detected as QFT conversion from negative to positive, are prioritized for preventive therapy (3) . However, QFT test results are confounded by immunological and analytical variability (4, 5) , which can result in false-positive conversions. In the absence of risk factors, interpretation of QFT is problematic (6) (7) (8) (9) , and false-positive QFT conversion may trigger unnecessary preventive therapy.
In high-burden settings, QFT conversion is also likely to represent Mtb infection (1, 10) , although preventive therapy is not universally recommended, owing to high risk of reinfection and low cost-effectiveness (3, 11) . However, such settings may be ideal for conducting clinical trials of prevention of Mtb infection (POI) by novel vaccines or TB preventive therapy, using QFT conversion as an efficacy endpoint. The POI strategy has been proposed as a cost-effective proof-ofconcept trial design to test vaccine candidates prior to more resourceintensive efficacy trials based on TB disease endpoints (12, 13) . A POI trial (registered with www.clinicaltrials.gov [NCT02075203] ) is being conducted to test whether bacillus Calmette-Guérin revaccination or boost vaccination with the novel subunit vaccine H4:IC31 can protect South African adolescents against acquisition of Mtb infection. The primary efficacy endpoint is QFT conversion from negative to positive, defined by the positivity cutoff IFN-g value of 0.35 IU/ml, as recommended by the manufacturer and the CDC (14) . However, the immunological and analytical variability of QFT tests (4, 5) potentially confounds interpretation of QFT conversion as a clinical trial endpoint.
Several investigators have proposed caution in interpreting QFT results close to the assay cutoff, where assay variability is more likely associated with discordant results upon serial testing, and they have suggested the introduction of a zone of uncertainty (9, 15) . Observations based on serial QFT testing in South Africa (16) and India (7, 17) suggest that this "uncertainty zone" lies between 0.2 and 0.7 IU/ml.
We aimed to identify and minimize sources of QFT assay variability to improve consistency of serial testing. We also report epidemiological and immunological evidence that supports a more rigorous definition of QFT conversion to account for the uncertainty of interpreting values between 0.2 and 0.7 IU/ml. We propose that this definition of QFT conversion is applicable as a more accurate estimate of subsequent risk of disease and as an endpoint for POI clinical trials.
Methods Study Populations and Procedures
Five separate cohorts of HIV-negative participants with varying degrees of Mtb exposure were studied to address different questions. Inclusion and exclusion criteria for each cohort are described in the online supplement. Cohort 1. Healthy adolescents were recruited at the South African Tuberculosis Vaccine Initiative (SATVI) in South Africa in an epidemiological and immunological cohort study described elsewhere (18) (19) (20) . The QFT assay was conducted according to the manufacturer's instructions. Baseline IFN-g values were compared with tuberculin skin test (TST) (RT23; Statens Serum Institut, Copenhagen, Denmark) results, and serial IFN-g values were used to stratify participants to assess prospective risk of TB progression.
Cohort 2. Healthy adults were recruited at SATVI to assess the effects of variation in the QFT manufacturer's standard operating procedures (SOP), as described in Table 1 .
Optimized QFT SOP stricter than the manufacturer's specifications (Table 1) were subsequently implemented and tested in cohorts 3, 4, and 5, which are detailed below.
Cohort 3. Healthy adults with no known exposure to Mtb were recruited at the Statens Serum Institut in Denmark.
Cohort 4. Adult patients with microbiologically confirmed TB disease were recruited by the Immunology Research Group at Stellenbosch University and at SATVI in Cape Town, South Africa.
Banked samples from cohorts 3 and 4 were analyzed at SATVI in a blinded fashion by the same operator and using the same ELISA batch to describe the distribution of IFN-g values in populations with known Mtb infection status.
Cohort 5. Healthy adolescents were recruited at SATVI in the POI vaccine trial (registered with www.clinicaltrials.gov [NCT02075203]), as described in the introductory section of the main text above. QFT was performed at screening and repeated 3 and 12 months later (see online supplement for study procedures). Interassay variability, distribution of baseline IFN-g values, and short-term conversion rates were determined in this cohort.
QFT
All quantitative QFT results were expressed as IFN-g concentration (IU/ml; calculated as TB antigen minus Nil), and qualitative results were defined according to the manufacturer's algorithm. To minimize the effects of known sources of variability (4) quality control checks were implemented within the boundaries of the manufacturer's instructions (Table 1) . These procedures were implemented without further testing when evidence derived from published studies was considered to be robust (Table 1) ; otherwise, they were tested in cohort 2. In addition to well-defined training and validation criteria for new operators, as well as participation in an external quality assurance program (run by the College of American Pathologists), an internal quality assurance (IQA) program was implemented. Large volumes of internal quality control (IQC) samples with low, medium, and high IFN-g concentrations were generated by appropriate dilution of plasma from stimulated whole blood in plasma from unstimulated whole blood. Hundreds individual plasma aliquots were cryopreserved and included in each ELISA run.
Statistical Analyses
Prism software (version 7; GraphPad Software, La Jolla, CA) was used to perform statistical analyses as described in each figure legend. In cohort 1, incidence of TB disease and rate ratios were calculated for different QFT conversion classes and compared with nonconverters (see online supplement for details).
Results

Immunological Evidence for Uncertainty Zone
Definition of a zone of uncertainty for QFT results has been based primarily on considerations about assay reproducibility (15, 16) . To determine if such an uncertainty zone was also supported by an independent immunological test (TST), we analyzed QFT and TST agreement in cohort 1 (see Figure E1 in the online supplement) (18) .
Among 5,357 adolescents who had QFT and TST performed at study baseline, 15% of participants with QFT IFN-g values less than 0.2 IU/ml displayed a positive TST (TST1; induration, >5 mm; cutoff defined elsewhere [18] ). By contrast, 53% of those with a negative QFT, but whose IFN-g value fell between 0.2 and 0.34 IU/ml, were TST1. In QFT1 adolescents, the proportions of TST1 individuals were 66% among those with IFN-g values between 0.35 and 0.7 IU/ml and 91% among those with IFN-g values greater than 0.7 IU/ml ( Figure 1 ). Overall, 43% of individuals with QFT IFN-g values between 0.2 and 0.7 IU/ml had discordant QFT and TST results, whereas concordance between QFT and TST was observed in greater than 85% of participants with QFT IFN-g values less than 0.2 or greater than 0.7 IU/ml.
Prognostic Significance of "Uncertain" QFT Conversion
We previously reported that recent QFT conversion, defined as a negative test (IFN-g ,0.35 IU/ml) followed by a positive test (IFN-g >0.35 IU/ml), was associated with significantly increased risk of TB disease (1) . In the present study, we aimed to determine how application of a more rigorous definition of QFT conversion, which accounts for uncertainty of IFN-g values between 0.2 and 0.7 IU/ml, influenced prospective TB risk in cohort 1. Compared with stringent QFT nonconverters (who maintained IFN-g ,0.2 IU/ml at Days 0, 360, and 720), stringent QFT converters (IFN-g ,0.2 IU/ml at Day 0 and .0.7 IU/ml at Day 360) had a significantly higher risk of developing TB disease ( Table 2) . By contrast, the risk of TB disease in "uncertain" QFT converters (IFN-g ,0.35 IU/ml at Day 0 and >0.35 IU/ml at Day 360, with at least one result within the uncertainty zone) was not different from that of stringent QFT nonconverters. Similar results (i.e., significantly higher TB risk in stringent QFT converters but not in "uncertain" QFT converters) were obtained when applying the conventional cutoff of 0.35 IU/ml to define QFT nonconverters (data not shown) or when defining "uncertain" QFT converters as IFN-g less than 0.2 IU/ml at Day 0 and IFN-g 0.2-0.7 IU/ml at Day 360 (Table E1 ). These results suggest that "uncertain" converters include a substantial number of "falsepositive" converters, potentially resulting from immunological and assay variability.
QFT Preanalytical Variability
An important source of variability in IFN-g values derives from laboratory procedures.
To reduce analytical variability of the QFT assay and improve consistency of longitudinal QFT testing, we investigated stricter SOP parameters (Table 1) . First, we assessed the combined effects of blood volume and incubation time by incubating sets of QFT tubes (Nil, TB antigen [Ag], mitogen) from eight healthy donors in cohort 2 (four QFT2 and four QFT1) containing 0.8 ml, 1 ml, or 1. observed at lower blood volumes (0.8 ml) and longer incubation times (24 h) ( Figure 2B ). We therefore restricted the blood volume to be collected into Nil and TB Ag tubes to 1 ml and constrained the incubation time to 16-20 hours for all subsequent tests.
Next, we evaluated the effects of transport and storage temperatures on IFN-g values in plasma samples following centrifugation ( Figure 2C Figure 2C ).
IFN-g ELISA Standard Curve
QFT kits sold in the United States (and approved by the Food and Drug Administration) contain eight IFN-g standards (ranging from 0 to 8 IU/ml), whereas the assay available in other countries contains only four IFN-g standards (ranging from 0 to 4 IU/ml). To evaluate the effects of applying these different standard curves, we compared IFN-g values extrapolated from four or eight IFN-g standards for QFT assays, run in parallel on the same plate, on 20 healthy donors in cohort 2. Samples analyzed with an 8-point standard curve yielded significantly higher IFN-g values than those calculated with a 4-point standard curve ( Figure 3A) . However, IFN-g values were highly correlated and deviated from equivalence only at concentrations greater than 4 IU/ml ( Figures 3B and E2 ).
QFT Analytical Variability
We also considered whether analyzing samples in single ELISA plate wells, as recommended by the manufacturer, rather than in triplicate was acceptable, because significant intraassay variability under identical conditions has been reported for QFT assays (5). In our hands, triplicate assays showed similar or lower variability than that reported in a published metaanalysis ( Figures 3C and 3D and [5] ). Triplicate measurements less than 0.8 IU/ml yielded a coefficient of variation below 30% (which dropped below 10% for higher values) and an SD below 0.15 IU/ml, with a few exceptions. On the basis of these results and the cost of the QFT ELISA, our protocol conformed to the manufacturer's recommendation to analyze samples in single wells.
QFT Interassay Variability
IFN-g ELISA variability over time was monitored by a newly established IQA program. Analyses of a first set of IQC samples included in each ELISA run for 15 consecutive months revealed that the ELISA batch was a source of significant variability ( Figure E3A ). We then implemented a preassessment procedure in which new ELISA kit batches were tested before those QFT kits were procured, with consistent performance relative to previous ELISAs (see footnote below Table 1 for acceptance criteria). A second set of IQC samples was then used to monitor 150 ELISA tests for over 18 months ( Figure 4A ). Overall, less than 15% variability was observed between assays and across operators and ELISA batches for IQC samples with medium and high IFN-g values (0.52 IU/ml and 1.62 IU/ml, respectively). An SD of 0.05 IU/ml was observed for the low IQC sample (0.07 IU/ml). Using the same ELISA batch, interoperator variability was less than 15% for medium and high IQC samples and less than 30% for the low IQC (see Figure E3B ). Additional pass/fail criteria, adapted from the Westgard rules (21), were also implemented to allow real-time assessment of each ELISA run prior to the release of each assay's results (see footnote below Table 1 ). Implementation of optimized QFT procedures (shown in Table 1 ) yielded significantly lower interassay variability than that indicated by historical data (2) obtained using standard QFT procedures ( Figure 4B ).
Interpretation of QFT Values within the Uncertainty Zone
No gold standard for detection of asymptomatic (latent) Mtb infection exists. To determine if the QFT assay cutoff at 0.35 IU/ml is optimal in a TB-endemic population, we employed the optimized SOP described in Table 1 to measure IFN-g values in healthy, Mtb-unexposed control subjects from Denmark (cohort 3; n = 50) and microbiologically confirmed TB cases from South Africa (cohort 4; n = 68) ( Figure 5A ). The standard QFT cutoff of 0.35 IU/ml yielded 100% specificity and 91% sensitivity. Because all Mtb-unexposed control subjects had IFN-g values less than 0.2 IU/ml, we explored whether a lower QFT cutoff would increase sensitivity. Applying a cutoff at 0.2 IU/ml, which coincides with the lower limit of the uncertainty zone, yielded 96% sensitivity, whereas the specificity remained at 100%. Interestingly, 9% of IFN-g values from TB cases fell between 0.2 and 0.7 IU/ml, whereas 87% of patients with TB had IFN-g greater than 0.7 IU/ml.
Finally, we implemented the optimized QFT SOP to screen healthy adolescents for the POI trial (cohort 5; n = 2,432). About 50% were QFT positive ( Figure 5B ). IFN-g values were evenly distributed around the assay cutoff of 0.35 IU/ml, and approximately 7% of IFN-g values fell into the uncertainty zone between 0.2 and 0.7 IU/ml. The IFN-g values around this zone were continuously distributed with no natural inflection points, even when the ratio (instead of subtraction) of TB Ag and Nil was considered ( Figure 5C ).
Interpretation of Serial QFT Results
Remarkably, 5.3% of QFT-negative adolescents enrolled in cohort 5 converted to a positive QFT result when retested 3 months later ( Figure 6A ), whereas no incident TB occurred. More than half of these converters (56.3%) had one of two consecutive IFN-g values within the uncertainty zone (0.2-0.7 IU/ml). When variability across these consecutive paired measurements was evaluated, a considerable overlap between some QFT nonconverters and "uncertain" QFT converters was noted ( Figure 6B ), suggesting that a substantial proportion of "uncertain" conversions results from immunological and technical variability around the assay cutoff. Of note, 49% percent of adolescents with an initial IFN-g value within 0.2-0.34 IU/ml converted to a positive test, whereas only 3% with an initial IFN-g value less than 0.2 IU/ml converted ( Figure 6C ). Among converters, adolescents with an initial IFN-g value less than 0.2 IU/ml were more likely to convert to an IFN-g value greater than 0.7 IU/ml (81%, Figure 6D ) than those with an initial IFN-g value within 0.2-0.34 IU/ml (18%; P , 0.0001). QFT was performed according to standard manufacturer's recommendations in an infant cohort (described in Reference 2) or according to optimized procedures described in Table 1 for cohort 5 (adolescents enrolled in the prevention of Mycobacterium tuberculosis infection trial). All included individuals had negative QFT test results (IFN-g ,0.35 IU/ml) at both time points, did not undergo tuberculin skin testing, and were not diagnosed with incident tuberculosis (TB) disease. Box-and-whisker plots denote median, interquartile range, and 1st-99th percentiles, respectively. P value was calculated by Mann-Whitney U test. The dotted line denotes the SD observed in the lower IQC sample shown in (A), which represents the expected interassay variability solely due to the IFN-g ELISA used. Ag = antigen.
Discussion
QFT conversion should identify individuals with recent Mtb infection who are at high risk of disease progression, allowing targeted intervention. However, interpretation of serial QFT tests is confounded by immunological and technical variability. In this paper, we highlight technical, immunological, and epidemiological factors that influence the interpretation and clinical significance of QFT assay conversions, supporting the establishment of an uncertainty zone between 0.2 and 0.7 IU/ml and a more rigorous definition of QFT conversion. Stringent conversion from IFN-g less than 0.2 to greater than 0.7 IU/ml was associated with a 10-fold higher incidence rate ratio of TB disease than stringent nonconversion with serial IFN-g values less than 0.2 IU/ml over 2 years. By contrast, "uncertain" converters, with at least one of two serial test results within 0.2-0.7 IU/ml, were not at higher risk than nonconverters, although this analysis was powered to detect only substantially increased risks (greater than fivefold rate ratios). We previously showed that "uncertain" QFT conversions to IFN-g values less than 0.7 IU/ml were associated with 50% probability of reversion (19) . Whether QFT reverters experience lower incidence of TB disease than persistent QFT1 and sustained converters is still unclear (19) , but it might contribute to the lower risk of TB disease observed in "uncertain" converters. The data in our present study suggest that a substantial proportion of "uncertain" QFT conversions may result from immunological and technical variability around the assay cutoff rather than from Mtb infection.
To minimize assay variability for longitudinal testing, we assessed preanalytical and analytical sources of variation, including previously unreported effects of transport temperature, standard curve, and ELISA batch, and we adapted our procedures accordingly. We showed that a 4-point standard curve was acceptable to calculate IFN-g values well above the assay cutoff of 0.35 IU/ml. We previously showed by serial plasma dilutions that, even when extrapolated from a 4-point standard curve, IFN-g values are quantitative up to 12 IU/ml (2) . At the time of implementation of our QFT IQA, we were not aware of any published guidelines about such programs. The IQA program proved invaluable for monitoring consistency of results and identifying sources of analytical variability, including continuous evaluation of trained operators and preassessment of IFN-g ELISA batches. Taken together, our results support the implementation of IQA programs to monitor intralaboratory performance of QFT, and QFT control panel reagents are now commercially available. Implementation of optimized QFT procedures, which are more stringent than the standard procedures recommended by the manufacturer, resulted in significant reduction of serial testing variability compared with historical data obtained by standard procedures.
In cohort 5 (POI trial), we observed that 5% of adolescents who were QFT2 at screening converted to a positive test within 3 months, which extrapolates to an annual infection rate of 20%. This is considerably higher than the previous estimate of 14% (19) . Overlap in shortterm interassay variability between some nonconverters and "uncertain" converters was observed, suggesting that at least some conversions may have resulted from assay variability, despite implementation of optimized laboratory procedures. Indeed, approximately half of adolescents with baseline IFN-g values between 0.2 and 0.34 IU/ml converted to greater than or equal to 0.35 IU/ml within 3 months, but 82% of these conversions were still within the uncertainty zone (IFN-g ,0.7 IU/ml). These results, together with the finding that 43% of individuals with IFN-g values between 0.2 and 0.7 IU/ml had a concomitant discordant TST result in cohort 1, suggest that QFT values in this range may also reflect heterogeneous immunological sensitization due to Mtb infection. This interpretation is also supported by the higher rates of QFT conversion after TST administration reported in individuals with HIV infection who had IFN-g values between 0.15 and 0.34 IU/ml, compared with those with lower IFN-g values (22) . Taken together, these data suggest that a substantial proportion of Mtb-sensitized individuals display a weak immune response falling in the lower range of the QFT uncertainty zone.
Because the QFT assay measures Mtbspecific immune responses that are typically not bimodally distributed (23) and are heterogeneous within and across populations, interpreting quantitative measurements close to the cutoff as evidence for Mtb infection is fraught with uncertainty (24, 25) . In this paper, we provide evidence that IFN-g values within the zone of uncertainty are consistent with both weak immune responses to Mtb and technical variability. These possible causes cannot be further teased apart, and failure to take this uncertainty zone into account when defining QFT conversion will inevitably lead to misclassifications. CDC guidelines for interpreting T-SPOT.TB (Oxford Immunotec, Marlborough, MA) test results already include criteria for interpreting borderline results, indicative of uncertain Mtb infection (14) . Our study supports the introduction of an uncertainty zone for QFT.
The epidemiological data that provide the basis for our interpretation of serial QFT results are subject to some limitations, which may restrict the generalizability of our findings. First, cohort 1 was one of the first large longitudinal studies assessing the performance of serial QFT in settings with a high TB burden. At that time, there was little information about sources of QFT variability, and therefore the assay was performed according to manufacturer's instructions and not with the optimized SOP used to generate the other results presented in this paper. Further, despite performing serial QFT in about 3,000 adolescents over 2 years, this sample size was still limited to accurately calculate the prospective risk of TB disease once participants were stratified by different QFT conversion definitions. Second, Mtbunexposed Danish negative control subjects (cohort 3) were recruited in a setting with low TB burden and may have lower baseline IFN-g levels than South African volunteers, owing to other genetic and/or environmental factors. Third, although patients with microbiologically confirmed TB are certainly infected with Mtb, they do not represent an optimal gold standard for asymptomatic Mtb infection. Finally, participants in the POI trial (cohort 5) were vaccinated with saline placebo, bacillus Calmette-Guérin, or H4:IC31 (1:1:1) between baseline and following QFT tests. Because we are currently blinded to treatment allocation, we cannot exclude the possibility that vaccination may have influenced either QFT conversion rates or IFN-g values at conversion, although neither of the investigational products contains antigens included in the QFT assay.
This work was undertaken to implement serial QFT testing to measure efficacy of novel TB vaccines to prevent Mtb infection. However, the results are relevant to other clinical and research settings where longitudinal assay consistency is essential. Because the risk of incident TB disease was highest for individuals with QFT conversion values from below to above the uncertainty zone (0.2-0.7 IU/ml), and because results within 0.2-0.7 IU/ml reflect weak immune responses and/or technical variability, we propose that stringent QFT conversions should be considered those with an initial IFN-g value less than 0.2 IU/ml followed by an IFN-g value greater than 0.7 IU/ml. This more rigorous QFT conversion definition should be applied in clinical trials as an exploratory endpoint to define acquisition of Mtb infection. Applicability of this more rigorous QFT conversion definition requires evaluation in independent studies in low-and high-TBendemic settings to identify individuals at high risk of TB disease for targeted preventive treatment. Because the QFTPlus assay, newly approved by the Food and Drug Administration, is in most respects identical to the QFT (Gold-In-Tube), we believe that our findings will likely also be generally applicable to the QFT-Plus assay. However, this requires experimental verification, and the boundaries for the uncertainty zone will need to be established.
Individuals who convert according to the manufacturer's specifications but do not meet this conversion definition should be closely followed and retested at a later date to confirm sustained QFT conversion. CDC guidelines for borderline IFN-g release assay results could be applied to one-time "uncertain" QFT results (i.e., repeating IFN-g release assay or performing a TST [14] ). n Author disclosures are available with the text of this article at www.atsjournals.org.
